MARKET

ARGX

ARGX

Argenx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

249.74
+5.28
+2.16%
Closed 16:10 09/18 EDT
OPEN
242.73
PREV CLOSE
244.46
HIGH
249.98
LOW
242.73
VOLUME
297.31K
TURNOVER
--
52 WEEK HIGH
272.74
52 WEEK LOW
103.75
MARKET CAP
11.76B
P/E (TTM)
-28.6258
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
argenx SE (ARGX): Hedge Fund Interest Inching Up
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index
Insider Monkey · 4d ago
argenx Management to Present at Upcoming Virtual Investor Conferences
September 2, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in several upcoming
GlobeNewswire · 09/02 06:00
Argen-X initiated at outperform with $275 price target at Raymond James
ARGX | A complete ARGX overview by MarketWatch. View the latest market news and prices, and trading information.
marketwatch.com · 08/25 12:13
Raymond James Initiates Coverage On argenx with Outperform Rating, Announces Price Target of $257
Raymond James analyst Danielle Brill initiates coverage on argenx (NASDAQ:ARGX) with a Outperform rating and announces Price Target of $257.
Benzinga · 08/25 11:02
J&J takeout of Momenta lifts argenx SE
Thinly traded argenx SE (ARGX) perks up 1% premarket on light volume on the heels of Johnson & Johnson's (JNJ) $6.5B takeout of Momenta Pharmaceuticals (MNTA).The Belgian biotech's antibody engineering technology is
Seekingalpha · 08/19 11:01
Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $281
Morgan Stanley maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $258 to $281.
Benzinga · 08/10 12:26
argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
August 4, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren
GlobeNewswire · 08/04 05:00
Argenx SE reports 1H results
Seeking Alpha · 07/30 05:10
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARGX stock price target is 255.62 with a high estimate of 291.20 and a low estimate of 191.79.
EPS
Institutional Holdings
Institutions: 225
Institutional Holdings: 31.44M
% Owned: 66.73%
Shares Outstanding: 47.11M
TypeInstitutionsShares
Increased
53
4.00M
New
64
499.26K
Decreased
49
1.11M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Non-Executive Chairman/Independent Director
Peter Verhaeghe
Chief Executive Officer/Co-Founder/Executive Director
Tim Van Hauwermeiren
Non-Executive Vice Chairman/Independent Director
Werner Lanthaler
Chief Financial Officer
Eric Castaldi
Chief Operating Officer
Keith Woods
Chief Scientific Officer
Hans de Haard
Vice President - Business Development
Arjen Lemmen
General Counsel
Dirk Beeusaert
Other
Wim Parys
Non-Executive Independent Director
James Daly
Non-Executive Independent Director
Joseph deBethizy
Non-Executive Independent Director
Pamela Klein
Non-Executive Independent Director
David Lacey
Non-Executive Independent Director
Joseph De Bethizy
Non-Executive Independent Director
Anthony Rosenberg
Non-Executive Independent Director
A.A. Rosenberg
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average ARGX stock price target is 255.62 with a high estimate of 291.20 and a low estimate of 191.79.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ARGX
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of argenx SE - ADR stock information, including NASDAQ:ARGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARGX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARGX stock methods without spending real money on the virtual paper trading platform.